发明申请
WO2023069888A1 ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
审中-公开
基本信息:
- 专利标题： ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
- 申请号：PCT/US2022/078192 申请日：2022-10-17
- 公开(公告)号：WO2023069888A1 公开(公告)日：2023-04-27
- 发明人： PU, Pu , ZHANG, Songling , JIN, Ying , MACWILLIAMS, Maria P. , FUNG, Man-Cheong , CHIU, Mark L.
- 申请人： TAVOTEK BIOTHERAPEUTICS (HONG KONG) LIMITED
- 申请人地址： Unit 1, 9/F, Wo Hing Commercial Building,
- 专利权人： TAVOTEK BIOTHERAPEUTICS (HONG KONG) LIMITED
- 当前专利权人： TAVOTEK BIOTHERAPEUTICS (HONG KONG) LIMITED
- 当前专利权人地址： Unit 1, 9/F, Wo Hing Commercial Building,
- 代理机构： FENG, Li et al.
- 优先权： US63/256,705 2021-10-18
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; C07K16/22 ; A61P35/00
摘要：
The disclosure provides antibodies and fragments targeting EGFR, VEGF, PD-L1, or cMET. The disclosure also provides multispecific antibodies that comprise a first variable domain that can bind the epidermal growth factor receptor (EGFR), a second variable domain that can bind cMET, and a third variable domain that can bind PD-L1 or VEGF. The multispecific antibodies are effective in treating cancers and/or other diseases, disorders, and conditions where pathogenesis is mediated by EGFR, VEGF or PD-L1, and cMET.
IPC结构图谱:
| C | 化学；冶金 |
| --C07 | 有机化学 |
| ----C07K | 肽 |
| ------C07K16/00 | 免疫球蛋白，例如，单克隆或多克隆抗体 |
| --------C07K16/18 | .来自动物或人的抵抗物质 |
| ----------C07K16/28 | ..抗受体，细胞表面抗原或细胞表面决定因子 |